WO2013150544A2 - Ivabradine hydrochloride solid dispersion - Google Patents
Ivabradine hydrochloride solid dispersion Download PDFInfo
- Publication number
- WO2013150544A2 WO2013150544A2 PCT/IN2013/000212 IN2013000212W WO2013150544A2 WO 2013150544 A2 WO2013150544 A2 WO 2013150544A2 IN 2013000212 W IN2013000212 W IN 2013000212W WO 2013150544 A2 WO2013150544 A2 WO 2013150544A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvent
- ivabradine
- hydro
- solid dispersion
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Definitions
- the present invention provides a compound of 7,8-dimethoxy-3-[3-[[(l S)-(4,5- dimethoxybenzocyclobutan- 1 -yl)methyl]methylamino]propy 1]- 1 ,3-de-hydro-7,8- dimethoxy-2H-3-benzazepin-2-one oxalate (de-hydro ivabradine oxalate salt) and process for its preparation.
- the present invention also provides a process for the purification of de- hydro ivabradine oxalate salt.
- the present invention further provides a novel process for the preparation of ivabradine using novel intermediate.
- the present invention further provides a novel amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
- Ivabradine hydrochloride is chemically, 7,8-dimethoxy-3-[3-[[(l S)-(4,5- dimethoxybenzocyclobutan-l -yl)methyl]methylamino]propyl]-l ,3,4,5-tetrahydro-7,8- dimethoxy-2H-3-benzazepin-2-one hydrochloride and has the structure formula I:
- Ivabradine hydrochloride is a novel medication used for the symptomatic management of stable angina pectoris. Ivabradine hydrochloride acts by reducing the heart rate in a mechanism different from beta blockers and calcium channel blockers, two commonly prescribed antianginal drugs. It is classified as a cardiotonic agent. It is marketed under the brand name Procoralan® by Abbott.
- ivabradine hydrochloride can be prepared by the condensation of (S)-N-[(4,5-dimethoxybenzocyclobut-lyl)methyl]-N-(methyl)amine with 7,8-dimethoxy-3-[3-iodopropyl]-l ,3-de-hydro -2H-3-benzazepin-2-one in acetone and potassium carbonate to obtain 7,8-dimethoxy-3-[3-[[(l S)-(4,5- dimethoxybenzocyclobutan-1 -yl)methyl]methylamino]propyl]-l ,3-de-hydro -7,8- dimethoxy-2H-3-benzazepin-2-one, and then reduced with palladium hydroxide in glacial acetic acid under the atmosphere of hydrogen gas to get ivabradine which is
- Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and/or conformations of the molecules in the crystal Lattice.
- polymorphs are different crystalline structures of the same pure substance in which the molecules have different arrangements and/or different configurations of the molecules.
- Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph.
- Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and Infrared spectrometry (IR).
- XRD X-ray diffraction
- DSC Differential Scanning Calorimetry
- IR Infrared spectrometry
- Solvent medium and mode of crystallization play very important role in obtaining one polymorphic Form over the other.
- Ivabradine and its hydrochloride salt can exist in different polymorphic Forms, which may differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
- U.S. patent no. 7,867,994 disclosed a crystalline Form a of ivabradine hydrochloride.
- U.S. patent no. 7,361,649 disclosed a crystalline Form ⁇ of ivabradine hydrochloride.
- U.S. patent no. 7,358,240 disclosed a crystalline Form ⁇ of ivabradine hydrochloride.
- European patent no. 1695710 disclosed a crystalline Form pd of ivabradine hydrochloride.
- Crystalline Form Z, Form X and Form K of ivabradine hydrochloride were disclosed in PCT application publication no. WO 201 1/098582.
- a novel amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier is stable, reproducible and so, the amorphous solid dispersion of ivabradine hydrochloride is suitable for formulating ivabradine hydrochloride.
- Normally amorphous Forms are hygroscopic.
- Amorphous solid dispersion of ivabradine hydrochloride is found to be non-hygroscopic.
- one object of the present invention is to provide a compound of 7,8- dimethoxy-3-[3-[[(l S)-(4,5-dimethoxybenzocyclobutan-l -yl)methyl]methylamino]- propyl]-l ,3-de-hydro-7,8-dimethoxy-2H-3-benzazepin-2-one oxalate (de-hydro ivabradine oxalate salt) and process for its preparation.
- Another object of the present invention is to provide a process for the purification of 7,8-dimethoxy-3-[3-[[(l S)-(4,5-dimethoxybenzocyclobutan-l -yl)methyl]methylamino] propyl]- l ,3-de-hydro-7,8-dimethoxy-2H-3-benzazepin-2 -one oxalate (de-hydro ivabradine oxalate salt).
- Another object of the present invention is to provide a process for the preparation of ivabradine using novel intermediate.
- Another object of the present invention is to provide amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
- the present invention provides 7,8-dimethoxy-3-[3-[[(l S)-(4,5- dimethoxybenzocyclobutan-l -yl)methyl]methylamino]propyl]-l ,3-de-hydro-7,8- dimethoxy-2H-3-benzazepin-2-one oxalate (de-hydro ivabradine oxalate salt) of formula
- the present invention provides a process for the preparation of de-hydro ivabradine oxalate salt of formula II, which comprises:
- step (b) dissolving residual solid obtained in step (b) in an ester solvent
- the present invention provides a process for the purification of de-hydro ivabradine oxalate salt of formula II, which comprises:
- step (a) heating the suspension obtained in step (a) at above 45°C;
- the present invention provides a novel process for the preparation of ivabradine using novel intermediate, which comprises:
- the present invention provides amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
- the present invention there is provided a process for the preparation of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, which comprises:
- pharmaceutically acceptable carriers selected form copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus
- the present invention there is provided a process for the preparation of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, which comprises:
- step (b) adding one or more pharmaceutically acceptable carriers selected form copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus to the solution obtained in step (b); and
- compositions comprising a therapeutically effective amount of amorphous solid dispersion of ivabradine hydrochloride along with a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient.
- Figure 1 is a powder X-ray diffractogram patterns of crystalline 7,8-dimethoxy-3- [3-[[( 1 S)-(4,5-dimethoxybenzocyclobutan- 1 -yl)methyl]methylamino]propyl]- 1 ,3-de- hydro-7,8-dimethoxy-2H-3-benzazepin-2-one oxalate (De-hydro ivabradine oxalate salt) of formula II.
- Figure 2 is a powder X-ray diffractogram patterns of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
- Powder X-ray diffraction spectrum was measured on a bruker AXS D8 advance powder X-ray diffractometer having a copper- ⁇ radiation. Approximately 500 mg of sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two- theta, at 0.020 degrees two theta per step and a step time of 1 second. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 kV and current 35 mA.
- room temperature refers to temperature at about 25 to 35°C.
- a process for the preparation of de-hydro ivabradine oxalate salt of formula II which comprises: a) condensing the (S)-N-[(4,5-dimethoxybenzocyclobut- l-yl)methyl]-N- (methyl)amine hydrochloride with 7,8-dimethoxy-3-[3-iodopropyl]-l,3-de-hydro - 2H-3-benzazepin-2-one in the presence of potassium carbonate or sodium carbonate and dimethylformamide;
- step (b) dissolving residual solid obtained in step (b) in an ester solvent
- the reaction mass is concentrated in step (b) by distilling off the solvent.
- the distilling off the solvent may be carried out at atmospheric pressure or at reduced pressure.
- the distillation may preferably be carried out until the solvent is almost completely distilled off.
- the ester solvent used in step (c) may preferably be a solvent or a mixture of solvents selected from ethyl acetate, methyl acetate, isopropyi acetate, tert-butyl methyl acetate and ethyl formate, and more preferably the ester solvent is ethyl acetate.
- the ketonic solvent used in step (d) may be a solvent or mixture of solvents selected from acetone, methyl ethyl ketone, methyl isobutyl ketone and diethyl ketone, and more preferably the ketonic solvent is acetone.
- Isolation of de-hydro ivabradine oxalate salt in step (e) may preferably be performed by conventional techniques such as centrifugati n and filtration.
- a process for the purification of de-hydro ivabradine oxalate salt of formula ⁇ which comprises: a) suspending de-hydro ivabradine oxalate salt in a nitrile solvent and optionally adding water;
- step (a) heating the suspension obtained in step (a) at above 45°C;
- highly pure de-hydro ivabradine oxalate salt refers to de-hydro ivabradine oxalate salt having the purity greater than about 98% by weight, preferably greater than about 99% by weight, more preferably greater than about 99.5% by weight.
- the nitrile solvent used in step (a) may be a solvent or a mixture of solvents selected from acetonitrile, propionitrile, butyronitrile and benzonitrile. More preferably the nitrile solvent is acetonitrile.
- the reaction in step (b) may preferably be heated at about 50 to 65°C.
- Highly pure de-hydro ivabradine oxalate salt may be isolated in step (c) by the methods known such as filtration or centrifugation.
- de-hydro ivabradine oxalate salt The content of de-hydro ivabradine oxalate salt is determined by High performance liquid chromatography (HPLC).
- a novel process for the preparation of ivabradine using novel intermediate which comprises: a) dissolving de-hydro ivabradine oxalate salt in an alcoholic solvent; b) adding palladium on carbon to the solution;
- the alcoholic solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from methanol, ethanol, isopropanoi, n-butanol and n-pentanol, and more preferably the alcoholic solvent is methanol.
- Removal of the solvent may be carried out in step (d) at atmospheric pressure or at reduced pressure. Removal of the solvent may preferably be carried out until the solvent is almost completely distilled off.
- the base used in step (f) may preferably be an organic base or an inorganic base selected from ammonium, sodium hydroxide or potassium hydroxide, and more preferably the base is sodium hydroxide.
- the ester solvent used in step (g) may preferably be a solvent or a mixture of solvents selected from ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate, and more preferably the ester solvent is ethyl acetate.
- reaction mass is concentrated in step (h) by distilling off the solvent.
- the distilling off the solvent may be carried out at atmospheric pressure or at reduced pressure.
- the distillation may preferably be carried out until the solvent is almost completely distilled off.
- amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier there is provided amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
- the powdered x-ray diffractogram (PXRD) of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier is shown in figure 2.
- Amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier is found to be stable.
- the pharmaceutically acceptable carriers may be one or more of copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus.
- a process for the preparation of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier which comprises:
- pharmaceutically acceptable carriers selected form copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus
- Ivabradine hydrochloride used in step (a) may preferably be ivabradine hydrochloride obtained by the known process.
- the solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from dimethyl sulfoxide, dimethylacetamide, methanol, ethanol, isopropanol, n- butanol and n-pentanol, and more preferably the solvents are dimethyl sulfoxide, dimethylformamide, methanol and n-butanol.
- the pharmaceutically acceptable carriers used in step (a) may be selected form copovidone or hydroxypropyl methylcellulose.
- the dissolution in step (a) may be performed, for example, by heating the mixture of ivabradine hydrochloride and one or more pharmaceutically acceptable carriers in the solvent.
- Drying in step (b) may preferably be carried out at about 70 to 90°C.
- a process for the preparation of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier which comprises:
- step (b) adding one or more pharmaceutically acceptable carriers selected form copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus to the solution obtained in step (b); and
- the solvent used in step (a) and step (b) may preferably be a solvent or a mixture of solvents selected from dimethyl sulfoxide, dimethylacetamide, methanol, ethanol, isopropanol, n-butanol and n-pentanol, and more preferably the solvents are dimethyl sulfoxide, dimethylformamide, methanol and n-butanol.
- the pharmaceutically acceptable carriers used in step (c) may be selected form copovidone or hydroxypropyl methylcellulose.
- Drying in step (d) may preferably be carried out at about 70 to 90°C.
- compositions comprising a therapeutically effective amount of amorphous solid dispersion of ivabradine hydrochloride along with a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient.
- the amorphous solid dispersion of ivabradine hydrochloride may preferably be formulated into tablets, capsules, suspensions, dispersions, injectables or other pharmaceutical forms.
- De-hydro ivabradine oxalate salt (100 gm; HPLC Purity: 96.5%) as obtained in example 1 was dissolved in acetonitrile (500 ml) and then heated to 50 to 55°C. The solution was stirred for 1 hour at 50 to 55°C and then cooled to room temperature. The contents were then stirred for 1 hour at room temperature and filtered. The solid obtained was dried to obtain 85 gm of de-hydro ivabradine oxalate salt.
- De-hydro ivabradine oxalate salt 100 gm was dissolved in a mixture of acetonitrile (400 ml) and water (100 ml), and then heated to 50 to 55°C. The solution was stirred for 1 hour at 50 to 55°C and then cooled to room temperature. The contents were then stirred for 1 hour at room temperature and filtered. The solid obtained was dried to obtain 80 gm of de-hydro ivabradine oxalate salt.
- De-hydro ivabradine oxalate salt (90 gm; HPLC Purity: 99.7%) as obtained in example 2 was dissolved in methanol (1510 ml) and then added palladium on carbon (45 gm). To the reaction mixture was applied hydrogen gas for 4 hours and filtered through hy-flow bed. The solvent was distilled off under vacuum at below 55°C and then added water (1000 ml). The pH of the reaction mass was adjusted to 9.0 to 9.5 with sodium hydroxide solution (20%) and then added ethyl acetate (1000 ml). The layers were separated and the aqueous layer was extracted with ethyl acetate. Combined organic layers were dried with sodium sulfate and then concentrated to obtain 52 gm of ivabradine. Chromatographic purity of ivabradine: 99.7%.
- Ivabradine (5 gm) as obtained in example 4 was dissolved in methanol (50 ml) and then pH was adjusted to 2.0 with a solution of hydrochloric acid in methanol (1 N). The solution was stirred for 10 minutes at room temperature and then added copovidone (5 gm). The solvent was distilled off under vacuum at below 65°C and then dried under vacuum at 70°C for 2 hours to obtain 9 gm of amorphous ivabradine hydrochloride solid dispersion with copovidone.
- Ivabradine (5 gm) was dissolved in methanol (50 ml) and then pH was adjusted to
- Example 5 was repeated using ethanol solvent instead of methanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with copovidone.
- ivabradine hydrochloride 5 gm
- copovidone 6 gm
- n-butanol 100 ml
- the solution was stirred for 15 minutes at room temperature and the solvent was distilled off under vacuum at below 75°C.
- the resulting solid was subjected to drying at 70°C for 4 hours to obtain 10 gm of amorphous ivabradine hydrochloride solid dispersion with copovidone.
- ivabradine hydrochloride (20 gm) and copovidone (4 gm) was dissolved in methanol (240 ml) at room temperature. The solution was stirred for 15 minutes at room temperature and the solvent was distilled off under vacuum at below 75°C. The resulting solid was subjected to drying at 70°C for 2 hours to obtain 22 gm of amorphous ivabradine hydrochloride solid dispersion with copovidone.
- Example 8 was repeated using dimethyl sulfoxide solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with copovidone.
- Example 1 1
- Example 8 was repeated using ethanol solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with copovidone.
- Example 8 was repeated using dimethylacetamide solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with copovidone.
- ivabradine hydrochloride (10 gm) and hydroxypropyl methylcellulose (10 gm) was dissolved in n-butanol (200 ml) at room temperature. The solution was stirred for 15 minutes at room temperature and the solvent was distilled off under vacuum at below 75°C. The resulting solid was subjected to drying at 70°C for 3 hours to obtain 19 gm of amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose.
- Example 13 was repeated using dimethyl sulfoxide solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose.
- Example 15 was repeated using dimethyl sulfoxide solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose.
- Example 13 was repeated using dimethylacetamide solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose.
- Example 13 was repeated using methanol solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose.
- Example 17 was repeated using methanol solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose.
- Example 13 was repeated using ethanol solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose.
- ivabradine hydrochloride (10 gm) and soluplus (8 gm) was dissolved in n-butanol (150 ml) at room temperature. The solution was stirred for 15 minutes at room temperature and the solvent was distilled off under vacuum at below 75°C. The resulting solid was subjected to drying at 70°C for 3 hours to obtain 17 gm of amorphous ivabradine hydrochloride solid dispersion with soluplus.
- De-hydro ivabradine oxalate salt (90 gm; HPLC Purity: 99.7%) as obtained in example 2 was dissolved in methanol (1510 ml) and then added palladium on carbon (45 gm). To the reaction mixture was applied hydrogen gas for 4 hours and filtered through hy-flow bed. The solvent was distilled off under vacuum at below 55°C and then added water (1000 ml). The pH of the reaction mass was adjusted to 9.0 to 9.5 with sodium hydroxide solution (20%) and then added ethyl acetate (1000 ml). The layers were separated and the aqueous layer was extracted with ethyl acetate.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
The present invention provides a compound of 7,8-dimethoxy-3-[3-[[(1S)-(4,5-dimethoxybenzocyclobutan-1-yl)methyl]methylamino]propyl]-1,3-de-hydro-7,8-dimethoxy-2H-3-benzazepin-2-one oxalate (de-hydro ivabradine oxalate salt) and process for its preparation. The present invention also provides a process for the purification of de-hydro ivabradine oxalate salt. The present invention further provides a novel process for the preparation of ivabradine using novel intermediate. The present invention further provides a novel amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
Description
IVABRADINE HYDROCHLORIDE SOLID DISPERSION
This application claims the benefit of Indian patent Application No. 1309/CHE/2012, filed on April 02, 2012, which is incorporated herein by reference. Filed of the Invention
The present invention provides a compound of 7,8-dimethoxy-3-[3-[[(l S)-(4,5- dimethoxybenzocyclobutan- 1 -yl)methyl]methylamino]propy 1]- 1 ,3-de-hydro-7,8- dimethoxy-2H-3-benzazepin-2-one oxalate (de-hydro ivabradine oxalate salt) and process for its preparation. The present invention also provides a process for the purification of de- hydro ivabradine oxalate salt. The present invention further provides a novel process for the preparation of ivabradine using novel intermediate. The present invention further provides a novel amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
Background of the Invention
Ivabradine hydrochloride is chemically, 7,8-dimethoxy-3-[3-[[(l S)-(4,5- dimethoxybenzocyclobutan-l -yl)methyl]methylamino]propyl]-l ,3,4,5-tetrahydro-7,8- dimethoxy-2H-3-benzazepin-2-one hydrochloride and has the structure formula I:
Ivabradine hydrochloride is a novel medication used for the symptomatic management of stable angina pectoris. Ivabradine hydrochloride acts by reducing the heart rate in a mechanism different from beta blockers and calcium channel blockers, two commonly prescribed antianginal drugs. It is classified as a cardiotonic agent. It is marketed under the brand name Procoralan® by Abbott.
Ivabradine and its hydrochloride salt were disclosed in U.S. patent no.5,296,482 ('482 patent). According to the '482 patent, ivabradine hydrochloride can be prepared by
the condensation of (S)-N-[(4,5-dimethoxybenzocyclobut-lyl)methyl]-N-(methyl)amine with 7,8-dimethoxy-3-[3-iodopropyl]-l ,3-de-hydro -2H-3-benzazepin-2-one in acetone and potassium carbonate to obtain 7,8-dimethoxy-3-[3-[[(l S)-(4,5- dimethoxybenzocyclobutan-1 -yl)methyl]methylamino]propyl]-l ,3-de-hydro -7,8- dimethoxy-2H-3-benzazepin-2-one, and then reduced with palladium hydroxide in glacial acetic acid under the atmosphere of hydrogen gas to get ivabradine which is converted into its hydrochloride salt by the action of aqueous hydrochloric acid.
Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and/or conformations of the molecules in the crystal Lattice. Thus, in the strict sense, polymorphs are different crystalline structures of the same pure substance in which the molecules have different arrangements and/or different configurations of the molecules". Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph. It is therefore important to investigate all solid forms of a drug, including all polymorphic forms, and to determine the stability, dissolution and flow properties of each polymorphic form. Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and Infrared spectrometry (IR).
Solvent medium and mode of crystallization play very important role in obtaining one polymorphic Form over the other.
Ivabradine and its hydrochloride salt can exist in different polymorphic Forms, which may differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
U.S. patent no. 7,867,994 disclosed a crystalline Form a of ivabradine hydrochloride.
U.S. patent no. 7,361,649 disclosed a crystalline Form β of ivabradine hydrochloride.
U.S. patent no. 7,361,650 disclosed a crystalline Form γ of ivabradine hydrochloride.
U.S. patent no. 7,358,240 disclosed a crystalline Form δ of ivabradine hydrochloride.
U.S. patent no. 7,361,651 disclosed a crystalline Form yd of ivabradine hydrochloride.
U.S. patent no. 7,384,932 disclosed a crystalline Form 6d of ivabradine hydrochloride.
European patent no. 1695710 disclosed a crystalline Form pd of ivabradine hydrochloride.
PCT application publication no. WO 2008/065681 disclosed crystalline Form I of ivabradine hydrochloride.
PCT application publication no. WO 2008/146308 disclosed amorphous ivabradine hydrochloride.
Crystalline Form Z, Form X and Form K of ivabradine hydrochloride were disclosed in PCT application publication no. WO 201 1/098582.
We have found a novel compound of 7,8-dimethoxy-3-[3-[[(lS)-(4,5- dimethoxybenzocyclobutan-l-yl)methyl]methylamino]propyl]-l,3-de-hydro-7,8- dimethoxy-2H-3-benzazepin-2-one oxalate (de-hydro ivabradine oxalate salt) is useful intermediate for the preparation of ivabradine.
We have also found a novel process for the preparation of ivabradine using novel intermediate.
We have also found a novel amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier. The amorphous solid dispersion of ivabradine hydrochloride is stable, reproducible and so, the amorphous solid dispersion of ivabradine hydrochloride is suitable for formulating ivabradine hydrochloride. Normally amorphous Forms are hygroscopic. Amorphous solid dispersion of ivabradine hydrochloride is found to be non-hygroscopic.
Thus, one object of the present invention is to provide a compound of 7,8- dimethoxy-3-[3-[[(l S)-(4,5-dimethoxybenzocyclobutan-l -yl)methyl]methylamino]- propyl]-l ,3-de-hydro-7,8-dimethoxy-2H-3-benzazepin-2-one oxalate (de-hydro ivabradine oxalate salt) and process for its preparation.
Another object of the present invention is to provide a process for the purification of 7,8-dimethoxy-3-[3-[[(l S)-(4,5-dimethoxybenzocyclobutan-l -yl)methyl]methylamino] propyl]- l ,3-de-hydro-7,8-dimethoxy-2H-3-benzazepin-2 -one oxalate (de-hydro ivabradine oxalate salt).
Another object of the present invention is to provide a process for the preparation of ivabradine using novel intermediate.
Another object of the present invention is to provide amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it. Summary of the Invention
In one aspect, the present invention provides 7,8-dimethoxy-3-[3-[[(l S)-(4,5- dimethoxybenzocyclobutan-l -yl)methyl]methylamino]propyl]-l ,3-de-hydro-7,8- dimethoxy-2H-3-benzazepin-2-one oxalate (de-hydro ivabradine oxalate salt) of formula
II:
.Oxalate II
In another aspect, the present invention provides a process for the preparation of de-hydro ivabradine oxalate salt of formula II, which comprises:
a) condensing the (S)-N-[(4,5-dimethoxybenzocyclobut-l -yl)methyl]-N- (methyl)amine hydrochloride with 7,8-dimethoxy-3-[3-iodopropyl]-l ,3-de-hydro - 2H-3-benzazepin-2-one in the presence of potassium carbonate or sodium carbonate and dimethylformamide;
b) concentrating the reaction mass to obtain a residual solid;
c) dissolving residual solid obtained in step (b) in an ester solvent;
d) adding a solution of oxalic acid in a ketonic solvent to the solution; and
e) isolating the de-hydro ivabradine oxalate salt.
In another aspect, the present invention provides a process for the purification of de-hydro ivabradine oxalate salt of formula II, which comprises:
a) suspending de-hydro ivabradine oxalate salt in a nitrile solvent and optionally adding water;
b) heating the suspension obtained in step (a) at above 45°C; and
c) isolating the highly pure de-hydro ivabradine oxalate salt.
In another aspect, the present invention provides a novel process for the preparation of ivabradine using novel intermediate, which comprises:
a) dissolving de-hydro ivabradine oxalate salt in an alcoholic solvent;
b) adding palladium on carbon to the solution;
c) applying hydrogen gas to the reaction mass;
d) removing the solvent to obtain a residual mass;
e) adding water to the residual mass;
f) adjusting the pH of the reaction mass to about 9.0 to 10.0 with a base;
g) adding an ester solvent to the reaction mass; and
h) concentrating the reaction mass to obtain ivabradine.
In another aspect, the present invention provides amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
In another aspect, the present invention there is provided a process for the preparation of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, which comprises:
a) dissolving a mixture of ivabradine hydrochloride and one or more pharmaceutically acceptable carriers selected form copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus in a solvent; and
b) removing the solvent by drying at about 60 to 100 C to obtain amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
In another aspect, the present invention there is provided a process for the preparation of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, which comprises:
a) preparing a solution comprising ivabradine in a solvent;
b) adjusting the pH of the solution to about 2.0 to 3.0 with hydrochloric acid in a solvent;
c) adding one or more pharmaceutically acceptable carriers selected form copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus to the solution obtained in step (b); and
d) removing the solvent by drying at about 60 to 100°C to obtain amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
Yet in another aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of amorphous solid dispersion of ivabradine hydrochloride along with a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient.
Brief Description of the Drawing
Figure 1 is a powder X-ray diffractogram patterns of crystalline 7,8-dimethoxy-3- [3-[[( 1 S)-(4,5-dimethoxybenzocyclobutan- 1 -yl)methyl]methylamino]propyl]- 1 ,3-de- hydro-7,8-dimethoxy-2H-3-benzazepin-2-one oxalate (De-hydro ivabradine oxalate salt) of formula II.
Figure 2 is a powder X-ray diffractogram patterns of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
Powder X-ray diffraction spectrum was measured on a bruker AXS D8 advance powder X-ray diffractometer having a copper-Κα radiation. Approximately 500 mg of
sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two- theta, at 0.020 degrees two theta per step and a step time of 1 second. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 kV and current 35 mA.
Detailed Description of the Invention
The term "room temperature" refers to temperature at about 25 to 35°C.
According to one aspect of the present invention, there is provided 7,8-dimethoxy- 3-[3-[[(l S)-(4,5-dimethoxybenzocyclobutan-l-yl)methyl]methylamino]-propyl]-l ,3-de- hydro-7,8-dimethoxy-2H-3-benzazepin-2-one oxalate (De-hydro ivabradine oxalate salt) of formula II:
.Oxalate II
According to another aspect of the present invention, there is provided a process for the preparation of de-hydro ivabradine oxalate salt of formula II, which comprises: a) condensing the (S)-N-[(4,5-dimethoxybenzocyclobut- l-yl)methyl]-N- (methyl)amine hydrochloride with 7,8-dimethoxy-3-[3-iodopropyl]-l,3-de-hydro - 2H-3-benzazepin-2-one in the presence of potassium carbonate or sodium carbonate and dimethylformamide;
b) concentrating the reaction mass to obtain a residual solid;
c) dissolving residual solid obtained in step (b) in an ester solvent;
d) adding a solution of oxalic acid in a ketonic solvent to the solution; and
e) isolating the de-hydro ivabradine oxalate salt.
Preferably the reaction mass is concentrated in step (b) by distilling off the solvent. The distilling off the solvent may be carried out at atmospheric pressure or at reduced
pressure. The distillation may preferably be carried out until the solvent is almost completely distilled off.
The ester solvent used in step (c) may preferably be a solvent or a mixture of solvents selected from ethyl acetate, methyl acetate, isopropyi acetate, tert-butyl methyl acetate and ethyl formate, and more preferably the ester solvent is ethyl acetate.
Preferably the ketonic solvent used in step (d) may be a solvent or mixture of solvents selected from acetone, methyl ethyl ketone, methyl isobutyl ketone and diethyl ketone, and more preferably the ketonic solvent is acetone.
Isolation of de-hydro ivabradine oxalate salt in step (e) may preferably be performed by conventional techniques such as centrifugati n and filtration.
According to another aspect of the present invention, there is provided a process for the purification of de-hydro ivabradine oxalate salt of formula Π, which comprises: a) suspending de-hydro ivabradine oxalate salt in a nitrile solvent and optionally adding water;
b) heating the suspension obtained in step (a) at above 45°C; and
c) isolating the highly pure de-hydro ivabradine oxalate salt.
The term "highly pure de-hydro ivabradine oxalate salt" refers to de-hydro ivabradine oxalate salt having the purity greater than about 98% by weight, preferably greater than about 99% by weight, more preferably greater than about 99.5% by weight.
Preferably the nitrile solvent used in step (a) may be a solvent or a mixture of solvents selected from acetonitrile, propionitrile, butyronitrile and benzonitrile. More preferably the nitrile solvent is acetonitrile.
The reaction in step (b) may preferably be heated at about 50 to 65°C.
Highly pure de-hydro ivabradine oxalate salt may be isolated in step (c) by the methods known such as filtration or centrifugation.
The content of de-hydro ivabradine oxalate salt is determined by High performance liquid chromatography (HPLC).
According to another aspect of the present invention, there is provided a novel process for the preparation of ivabradine using novel intermediate, which comprises: a) dissolving de-hydro ivabradine oxalate salt in an alcoholic solvent;
b) adding palladium on carbon to the solution;
c) applying hydrogen gas to the reaction mass;
d) removing the solvent to obtain a residual mass;
e) adding water to the residual mass;
f) adjusting the pH of the reaction mass to about 9.0 to 10.0 with a base;
g) adding an ester solvent to the reaction mass; and
h) concentrating the reaction mass to obtain ivabradine.
The alcoholic solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from methanol, ethanol, isopropanoi, n-butanol and n-pentanol, and more preferably the alcoholic solvent is methanol.
Removal of the solvent may be carried out in step (d) at atmospheric pressure or at reduced pressure. Removal of the solvent may preferably be carried out until the solvent is almost completely distilled off.
The base used in step (f) may preferably be an organic base or an inorganic base selected from ammonium, sodium hydroxide or potassium hydroxide, and more preferably the base is sodium hydroxide.
The ester solvent used in step (g) may preferably be a solvent or a mixture of solvents selected from ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate, and more preferably the ester solvent is ethyl acetate.
Preferably the reaction mass is concentrated in step (h) by distilling off the solvent.
The distilling off the solvent may be carried out at atmospheric pressure or at reduced pressure. The distillation may preferably be carried out until the solvent is almost completely distilled off.
According to another aspect of the present invention, there is provided amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
The powdered x-ray diffractogram (PXRD) of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier is shown in figure 2.
Amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier is found to be stable.
Preferably the pharmaceutically acceptable carriers may be one or more of copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus.
According to another aspect of the present invention, there is provided a process for the preparation of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, which comprises:
a) dissolving a mixture of ivabradine hydrochloride and one or more pharmaceutically acceptable carriers selected form copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus in a solvent; and b) removing the solvent by drying at about 60 to 100°C to obtain amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
Ivabradine hydrochloride used in step (a) may preferably be ivabradine hydrochloride obtained by the known process.
The solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from dimethyl sulfoxide, dimethylacetamide, methanol, ethanol, isopropanol, n- butanol and n-pentanol, and more preferably the solvents are dimethyl sulfoxide, dimethylformamide, methanol and n-butanol.
Preferably the pharmaceutically acceptable carriers used in step (a) may be selected form copovidone or hydroxypropyl methylcellulose.
The dissolution in step (a) may be performed, for example, by heating the mixture of ivabradine hydrochloride and one or more pharmaceutically acceptable carriers in the solvent.
Drying in step (b) may preferably be carried out at about 70 to 90°C.
According to another aspect of the present invention, there is provided a process for the preparation of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier, which comprises:
a) preparing a solution comprising ivabradine in a solvent;
b) adjusting the pH of the solution to about 2.0 to 3.0 with hydrochloric acid in a solvent;
c) adding one or more pharmaceutically acceptable carriers selected form copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus to the solution obtained in step (b); and
d) removing the solvent by drying at about 60 to 100°C to obtain amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
The solvent used in step (a) and step (b) may preferably be a solvent or a mixture of solvents selected from dimethyl sulfoxide, dimethylacetamide, methanol, ethanol, isopropanol, n-butanol and n-pentanol, and more preferably the solvents are dimethyl sulfoxide, dimethylformamide, methanol and n-butanol.
Preferably the pharmaceutically acceptable carriers used in step (c) may be selected form copovidone or hydroxypropyl methylcellulose.
Drying in step (d) may preferably be carried out at about 70 to 90°C.
According to another aspect of the present invention, there is provided pharmaceutical compositions comprising a therapeutically effective amount of amorphous solid dispersion of ivabradine hydrochloride along with a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient. The amorphous solid dispersion of ivabradine hydrochloride may preferably be formulated into tablets, capsules, suspensions, dispersions, injectables or other pharmaceutical forms.
The invention will now be further described by the following examples, which are illustrative rather than limiting.
Examples
Example 1 :
Preparation of 7,8-dimethoxy-3-[3-'[[(lS)-(4,5-dimethoxybenzocyclobutan-l- yl)methyl]methylamino]propyl]-l,3-de-hydro-7,8-dimethoxy-2H-3-benzazepin-2-one oxalate (De-hydro ivabradine oxalate salt)
3-[3-Iodopropyl]-7,8-dimethoxy-l H-3-benzazepin-2(3H)-one (100 gm), dimethylformamide (800 ml), potassium carbonate (140 gm) and (S)-N-[(4,5-
dimethoxybenzocyclobut-l-yl)-methyl]-N-(methyl)amine hydrochloride (40 gm) were added and then heated to 40 to 45°C. The reaction mass was maintained for 17 hours at 40 to 45°C and then cooled to room temperature. To the reaction mass were added hydrochloric acid (IN, 3000 ml) and ethyl acetate (2000 ml). The layers were separated and the aqueous layer was extracted with ethyl acetate. Combined organic layers were dried with sodium sulfate and then concentrated to obtain a residual solid. To the residual solid was added ethyl acetate (750 ml) and then added a solution of oxalic acid (27 gm) in acetone (100 ml). The reaction mass was stirred for 2 hours at room temperature and filtered. The solid obtained was dried to obtain 90 gm of de-hydro ivabradine oxalate salt. Chromatographic purity of de-hydro ivabradine oxalate salt: 96.5%.
Example 2:
Purification of de-hydro ivabradine oxalate salt
De-hydro ivabradine oxalate salt (100 gm; HPLC Purity: 96.5%) as obtained in example 1 was dissolved in acetonitrile (500 ml) and then heated to 50 to 55°C. The solution was stirred for 1 hour at 50 to 55°C and then cooled to room temperature. The contents were then stirred for 1 hour at room temperature and filtered. The solid obtained was dried to obtain 85 gm of de-hydro ivabradine oxalate salt.
Chromatographic purity of de-hydro ivabradine oxalate salt: 99.7%.
Example 3:
Purification of de-hydro ivabradine oxalate salt
De-hydro ivabradine oxalate salt (100 gm) was dissolved in a mixture of acetonitrile (400 ml) and water (100 ml), and then heated to 50 to 55°C. The solution was stirred for 1 hour at 50 to 55°C and then cooled to room temperature. The contents were then stirred for 1 hour at room temperature and filtered. The solid obtained was dried to obtain 80 gm of de-hydro ivabradine oxalate salt.
Chromatographic purity of de-hydro ivabradine oxalate salt: 99.5%. Example 4:
Preparation of ivabradine
De-hydro ivabradine oxalate salt (90 gm; HPLC Purity: 99.7%) as obtained in example 2 was dissolved in methanol (1510 ml) and then added palladium on carbon (45 gm). To the reaction mixture was applied hydrogen gas for 4 hours and filtered through hy-flow bed. The solvent was distilled off under vacuum at below 55°C and then added water (1000 ml). The pH of the reaction mass was adjusted to 9.0 to 9.5 with sodium hydroxide solution (20%) and then added ethyl acetate (1000 ml). The layers were separated and the aqueous layer was extracted with ethyl acetate. Combined organic layers were dried with sodium sulfate and then concentrated to obtain 52 gm of ivabradine. Chromatographic purity of ivabradine: 99.7%.
Example 5:
Preparation of amorphous ivabradine hydrochloride solid dispersion with copovidone
Ivabradine (5 gm) as obtained in example 4 was dissolved in methanol (50 ml) and then pH was adjusted to 2.0 with a solution of hydrochloric acid in methanol (1 N). The solution was stirred for 10 minutes at room temperature and then added copovidone (5 gm). The solvent was distilled off under vacuum at below 65°C and then dried under vacuum at 70°C for 2 hours to obtain 9 gm of amorphous ivabradine hydrochloride solid dispersion with copovidone.
Example 6:
Preparation of amorphous ivabradine hydrochloride solid dispersion with copovidone
Ivabradine (5 gm) was dissolved in methanol (50 ml) and then pH was adjusted to
2.0 with a solution of hydrochloric acid in methanol (1 N). The solution was stirred for 10 minutes at room temperature and then added copovidone (1 gm). The solvent was distilled off under vacuum at below 65°C and then added cyclohexane (25 ml) under stirring. The separated solid was filtered and then dried to obtain 6 gm of amorphous ivabradine hydrochloride solid dispersion with copovidone.
Example 7:
Preparation of amorphous ivabradine hydrochloride solid dispersion with copovidone
Example 5 was repeated using ethanol solvent instead of methanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with copovidone.
Example 8:
Preparation of amorphous ivabradine hydrochloride solid dispersion with copovidone
A mixture of ivabradine hydrochloride (5 gm) and copovidone (6 gm) was dissolved in n-butanol (100 ml) at room temperature. The solution was stirred for 15 minutes at room temperature and the solvent was distilled off under vacuum at below 75°C. The resulting solid was subjected to drying at 70°C for 4 hours to obtain 10 gm of amorphous ivabradine hydrochloride solid dispersion with copovidone.
Example 9:
Preparation of amorphous ivabradine hydrochloride solid dispersion with copovidone
A mixture of ivabradine hydrochloride (20 gm) and copovidone (4 gm) was dissolved in methanol (240 ml) at room temperature. The solution was stirred for 15 minutes at room temperature and the solvent was distilled off under vacuum at below 75°C. The resulting solid was subjected to drying at 70°C for 2 hours to obtain 22 gm of amorphous ivabradine hydrochloride solid dispersion with copovidone.
Example 10:
Preparation of amorphous ivabradine hydrochloride solid dispersion with copovidone
Example 8 was repeated using dimethyl sulfoxide solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with copovidone.
Example 1 1 :
Preparation of amorphous ivabradine hydrochloride solid dispersion with copovidone
Example 8 was repeated using ethanol solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with copovidone.
Example 12:
Preparation of amorphous ivabradine hydrochloride solid dispersion with copovidone
Example 8 was repeated using dimethylacetamide solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with copovidone.
Example 13:
Preparation of amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose
A mixture of ivabradine hydrochloride (10 gm) and hydroxypropyl methylcellulose (10 gm) was dissolved in n-butanol (200 ml) at room temperature. The solution was stirred for 15 minutes at room temperature and the solvent was distilled off under vacuum at below 75°C. The resulting solid was subjected to drying at 70°C for 3 hours to obtain 19 gm of amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose.
Example 14:
Preparation of amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose
Example 13 was repeated using dimethyl sulfoxide solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose.
Example 15:
Preparation of amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose
Example 13 was repeated using dimethylacetamide solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose.
Example 16:
Preparation of amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose
Example 13 was repeated using methanol solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose. Example 17:
Preparation of amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose
Example 13 was repeated using ethanol solvent instead of n-butanol solvent to obtain amorphous ivabradine hydrochloride solid dispersion with hydroxypropyl methylcellulose.
Example 18:
Preparation of amorphous ivabradine hydrochloride solid dispersion with polyethylene glycol
A mixture of ivabradine hydrochloride (5 gm) and polyethylene glycol (4 gm) was dissolved in n-butanol (80 ml) at room temperature. The solution was stirred for 15 minutes at room temperature and the solvent was distilled off under vacuum at below 75°C. The resulting solid was subjected to drying at 70°C for 2 hours to obtain 8 gm of amorphous ivabradine hydrochloride solid dispersion with polyethylene glycol.
Example 19:
Preparation of amorphous ivabradine hydrochloride solid dispersion with ethyl cellulose
A mixture of ivabradine hydrochloride (20 gm) and ethyl cellulose (18 gm) was dissolved in n-butanol (300 ml) at room temperature. The solution was stirred for 15 minutes at room temperature and the solvent was distilled off under vacuum at below 75°C. The resulting solid was subjected to drying at 70°C for 4 hours to obtain 35 gm of amorphous ivabradine hydrochloride solid dispersion with ethyl cellulose. Example 20:
Preparation of amorphous ivabradine hydrochloride solid dispersion with soluplus
A mixture of ivabradine hydrochloride (10 gm) and soluplus (8 gm) was dissolved in n-butanol (150 ml) at room temperature. The solution was stirred for 15 minutes at room temperature and the solvent was distilled off under vacuum at below 75°C. The resulting solid was subjected to drying at 70°C for 3 hours to obtain 17 gm of amorphous ivabradine hydrochloride solid dispersion with soluplus.
Example 21 :
Preparation of amorphous ivabradine hydrochloride solid dispersion with copovidone
De-hydro ivabradine oxalate salt (90 gm; HPLC Purity: 99.7%) as obtained in example 2 was dissolved in methanol (1510 ml) and then added palladium on carbon (45 gm). To the reaction mixture was applied hydrogen gas for 4 hours and filtered through hy-flow bed. The solvent was distilled off under vacuum at below 55°C and then added water (1000 ml). The pH of the reaction mass was adjusted to 9.0 to 9.5 with sodium hydroxide solution (20%) and then added ethyl acetate (1000 ml). The layers were separated and the aqueous layer was extracted with ethyl acetate. Combined organic layers were dried with sodium sulfate and then added methanol (50 ml). The pH of the solution was adjusted to 2.0 with a solution of hydrochloric acid in methanol (1 N). The solution was stirred for 10 minutes at room temperature and then added copovidone (50 gm). The
solvent was distilled off under vacuum at below 65 C and then dried under vacuum at 70°C for 4 hours to obtain 100 gm of amorphous ivabradine hydrochloride solid dispersion with copovidone.
Chromatographic purity of amorphous ivabradine hydrochloride solid dispersion with copovidone: 99.7%.
Claims
We claim:
1. A 7,8-dimethoxy-3-[3-[[(l S)-(4,5-dimethoxybenzocyclobutan-l -yl)methyl]methyl- amino]propyl]-l ,3-de-hydro-7,8-dimethoxy-2H-3-benzazepin-2-one oxalate (De- hydro ivabradine oxalate salt) of formula II:
.Oxalate
A process for the preparation of de-hydro ivabradine oxalate salt of formula II, which comprises:
a. condensing the (S)-N-[(4,5-dimethoxybenzocyclobut-l -yl)methyl]-N- (methyl)amine hydrochloride with 7,8-dimethoxy-3-[3-iodopropyl]-l ,3-de- hydro-2H-3-benzazepin-2-one in the presence of potassium carbonate or sodium carbonate and dimethylformamide;
b. concentrating the reaction mass to obtain a residual solid;
c. dissolving residual solid obtained in step (b) in an ester solvent; d. adding a solution of oxalic acid in a ketonic solvent to the solution; and e. isolating the de-hydro ivabradine oxalate salt.
The process as claimed in claim 2, wherein the ester solvent used in step (c) is a solvent or a mixture of solvents selected from ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate.
The process as claimed in claim 2, wherein the ketonic solvent used in step (d) is a solvent or mixture of solvents selected from acetone, methyl ethyl ketone, methyl isobutyl ketone and diethyl ketone.
A process for the purification of de-hydro ivabradine oxalate salt of formula II, which comprises:
a. suspending de-hydro ivabradine oxalate salt in a nitrile solvent and optionally adding water;
b. heating the suspension obtained in step (a) at above 45°C; and
c. isolating the highly pure de-hydro ivabradine oxalate salt.
6. The process as claimed in claim 5, wherein the nitrile solvent used in step (a) is a solvent or a mixture of solvents selected from acetonitrile, propionitrile, butyronitrile and benzonitrile.
7. The process as claimed in claim 5, wherein the reaction in step (b) is heated at about 50 to 65°C.
8. A novel process for the preparation of ivabradine using novel intermediate, which comprises:
a. dissolving de-hydro ivabradine oxalate salt in an alcoholic solvent; b. adding palladium on carbon to the solution;
c. applying hydrogen gas to the reaction mass;
d. removing the solvent to obtain a residual mass;
e. adding water to the residual mass;
f. adjusting the pH of the reaction mass to about 9.0 to 10.0 with a base; g. adding an ester solvent to the reaction mass; and
h. concentrating the reaction mass to obtain ivabradine.
9. The process as claimed in claim 8, wherein the alcoholic solvent used in step (a) is a solvent or a mixture of solvents selected from methanol, ethanol, isopropanol, n- butanol and n-pentanol.
10. The process as claimed in claim 8, wherein the base used in step (f) is an organic base or an inorganic base selected from ammonium, sodium hydroxide or potassium hydroxide.
11. The process as claimed in claim 8, wherein the ester solvent used in step (c) is a solvent or a mixture of solvents selected from ethyl acetate, methyl acetate, isopropyl acetate, tert-butyl methyl acetate and ethyl formate.
12. An amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
13. The amorphous solid dispersion of claim 12, wherein the pharmaceutically acceptable carrier comprises one or more of copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus.
14. The amorphous solid dispersion of claim 12, having a powder X-ray diffractogram as shown in figure 2.
15. A process for the preparation of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier of claim 12, which comprises:
a. dissolving a mixture of ivabradine hydrochloride and one or more pharmaceutically acceptable carriers selected form copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus in a solvent; and
b. removing the solvent by drying at about 60 to 100°C to obtain amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
16. The process as claimed in claim 15, wherein the solvent used in step (a) is a solvent or a mixture of solvents selected from dimethyl sulfoxide, dimethylacetamide, methanol, ethanol, isopropanol, n-butanol and n-pentanol.
17. The process as claimed in claim 16, wherein the solvents are dimethyl sulfoxide, dimethylacetamide, methanol and n-butanol.
18. The process as claimed in claim 15, wherein the drying in step (b) is carried out at about 70 to 90°C.
19. A process for the preparation of amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier of claim 12, which comprises:
a. preparing a solution comprising ivabradine in a solvent;
b. adjusting the pH of the solution to about 2.0 to 3.0 with hydrochloric acid in a solvent;
c. adding one or more pharmaceutically acceptable carriers selected form copovidone, ethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol or soluplus to the solution; and
d. removing the solvent by drying at about 60 to 100 C to obtain amorphous solid dispersion of ivabradine hydrochloride in combination with a pharmaceutically acceptable carrier.
20. The process as claimed in claim 19, wherein the solvent used in step (a) and step (b) is a solvent or a mixture of solvents selected from dimethyl sulfoxide, dimethylacetamide, methanol, ethanol, isopropanol, n-butanol and n-pentanol.
21. The process as claimed in claim 20, wherein the solvents are dimethyl sulfoxide, dimethylacetamide, methanol and n-butanol.
22. The process as claimed in claim 19, wherein the drying in step (b) is carried out at about 70 to 90°C.
23. Pharmaceutical compositions comprising a therapeutically effective amount of amorphous solid dispersion of ivabradine hydrochloride along with a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient.
24. The pharmaceutical composition as claimed in claim 23, wherein the amorphous solid dispersion of ivabradine hydrochloride is formulated into tablets, capsules, suspensions, dispersions or injectables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1309/CHE/2012 | 2012-04-02 | ||
| IN1309CH2012 IN2012CH01309A (en) | 2012-04-02 | 2013-04-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2013150544A2 true WO2013150544A2 (en) | 2013-10-10 |
| WO2013150544A3 WO2013150544A3 (en) | 2013-12-05 |
Family
ID=49301127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2013/000212 WO2013150544A2 (en) | 2012-04-02 | 2013-04-01 | Ivabradine hydrochloride solid dispersion |
Country Status (2)
| Country | Link |
|---|---|
| IN (1) | IN2012CH01309A (en) |
| WO (1) | WO2013150544A2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104230808A (en) * | 2014-08-22 | 2014-12-24 | 苏州亚宝药物研发有限公司 | Amorphous ivabradine hydrochloride, and preparation method and application thereof |
| WO2015145234A1 (en) * | 2014-03-27 | 2015-10-01 | Laboratorio Chimico Internazionale S.P.A. | Ivabradine adsorbates |
| WO2016009314A1 (en) * | 2014-07-18 | 2016-01-21 | Sifavitor S.R.L. | "amorphous mixture of ivabradine and chrysin" |
| WO2016102423A1 (en) | 2014-12-22 | 2016-06-30 | Ratiopharm Gmbh | Composition comprising ivabradine in a dissolved form |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100087444A1 (en) * | 2007-03-12 | 2010-04-08 | Dr. Reddy's Laboratories Ltd. | Imatinib mesylate |
| US20100179316A1 (en) * | 2007-05-30 | 2010-07-15 | Ind-Swift Laboratories Limited | Process for the preparation of ivabradine hydrochloride and polymorph thereof |
| WO2011098582A2 (en) * | 2010-02-12 | 2011-08-18 | Krka, D.D., Novo Mesto | Novel forms of ivabradine hydrochloride |
| WO2011138625A1 (en) * | 2010-05-07 | 2011-11-10 | Richter Gedeon Nyrt. | Industrial process for the synthesis of ivabradine salts |
-
2013
- 2013-04-01 WO PCT/IN2013/000212 patent/WO2013150544A2/en active Application Filing
- 2013-04-01 IN IN1309CH2012 patent/IN2012CH01309A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100087444A1 (en) * | 2007-03-12 | 2010-04-08 | Dr. Reddy's Laboratories Ltd. | Imatinib mesylate |
| US20100179316A1 (en) * | 2007-05-30 | 2010-07-15 | Ind-Swift Laboratories Limited | Process for the preparation of ivabradine hydrochloride and polymorph thereof |
| WO2011098582A2 (en) * | 2010-02-12 | 2011-08-18 | Krka, D.D., Novo Mesto | Novel forms of ivabradine hydrochloride |
| WO2011138625A1 (en) * | 2010-05-07 | 2011-11-10 | Richter Gedeon Nyrt. | Industrial process for the synthesis of ivabradine salts |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015145234A1 (en) * | 2014-03-27 | 2015-10-01 | Laboratorio Chimico Internazionale S.P.A. | Ivabradine adsorbates |
| WO2016009314A1 (en) * | 2014-07-18 | 2016-01-21 | Sifavitor S.R.L. | "amorphous mixture of ivabradine and chrysin" |
| CN104230808A (en) * | 2014-08-22 | 2014-12-24 | 苏州亚宝药物研发有限公司 | Amorphous ivabradine hydrochloride, and preparation method and application thereof |
| WO2016102423A1 (en) | 2014-12-22 | 2016-06-30 | Ratiopharm Gmbh | Composition comprising ivabradine in a dissolved form |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013150544A3 (en) | 2013-12-05 |
| IN2012CH01309A (en) | 2015-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8779161B2 (en) | Asenapine maleate | |
| US9624207B2 (en) | Polymorphs of azilsartan medoxomil | |
| US8598341B2 (en) | Process for etravirine intermediate and polymorphs of etravirine | |
| EP2760853A1 (en) | Novel salts of alogliptin | |
| WO2013132511A1 (en) | Novel polymorph of lurasidone hydrochloride | |
| US20130131090A1 (en) | Salts of lapatinib | |
| WO2013150544A2 (en) | Ivabradine hydrochloride solid dispersion | |
| WO2012072689A1 (en) | Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size | |
| WO2015049698A2 (en) | Process for regorafenib | |
| SK7066Y1 (en) | Crystalline dihydrate bilastine | |
| WO2014009970A2 (en) | Linagliptin solid dispersion | |
| EP1789412A1 (en) | Crystalline alfuzosin base | |
| US8445506B2 (en) | Polymorphs of lopinavir | |
| WO2010146595A2 (en) | Novel polymorphs of flibanserin hydrochloride | |
| WO2014195977A2 (en) | Novel polymorphs of vismodegib | |
| CA2811912A1 (en) | Novel polymorphs of febuxostat | |
| CA2808731A1 (en) | Crystalline forms of maraviroc phosphate and process for maraviroc amorphous form | |
| US20150182458A1 (en) | Rufinamide solid dispersion | |
| WO2014013505A2 (en) | Amorphous vildagliptin | |
| US9381199B2 (en) | Linagliptin solid dispersion | |
| US20150291574A1 (en) | Novel polymorphs of azilsartan | |
| WO2011114336A1 (en) | Process for the isolation of ganciclovir intermediate | |
| WO2013080221A2 (en) | Process for alvimopan | |
| EP2459552A1 (en) | Polymorphic form of olmesartan medoxomil | |
| WO2013153558A1 (en) | Anhydrous form of moxifloxacin hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13772178 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 13772178 Country of ref document: EP Kind code of ref document: A2 |